SB221: A proof-of-concept study to assess the combination of SON-1010 (IL12-FHAB) and atezolizumab in patients with platinum-resistant ovarian cancer: Trial in Progress

Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

View Publication

Low Dose Interleukin-6 (SON-080) for Neuropathies: Toxicology and Clinical Plans

Presented at the 2024 American Association of Cancer Research (AACR) Annual Meeting

View Publication

SON-1210 - a novel bifunctional IL-12 / IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy

Published in Frontiers in Immunology

View Publication

Interim Analysis of a Phase 1 Study Using IL12-FHAB with Optimized Pharmacokinetics

Presented at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

View Publication

Clinical Development of a Novel Form of Interleukin-12 with Extended Pharmacokinetics

Presented at the 2023 American Association of Cancer Research (AACR) Annual Meeting

View Publication

An Innovative Human Platform for Targeted Delivery of Bispecific Interleukins to Tumors

Presented at the 2022 American Association of Cancer Research (AACR) Annual Meeting

View Publication

Toxicity Profile of Interleukin 12 Attached to a Fully Human Albumin Binding Domain (FHAB™) in Cynomolgus Macaques

Presented at the 2021 American Association of Cancer Research (AACR) Annual Meeting

View Publication

A Novel Strategy to Produce High Level and High Purity of Bioactive IL15 Fusion Proteins from Mammalian Cells

Protein Expression and Purification 148 (2018) 30–39

View Publication

In vivo Effect of Albumin Binding Domains (ABD) Attached to Immune Modulators

Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting

View Publication

Enhanced Efficacy of Immune Modulators with Albumin Binding Domains (ABD)

Presented at American Association of Cancer Research (AACR) Annual Meeting

View Publication